Adynovate (Antihemophilic factor [recombinant], PEGylated) for Hemophilia

Overview
Adynovate is approved by the Food and Drug Administration (FDA) to control and prevent bleeding episodes in adults and adolescents over the age of 12 with factor VIII deficiency due to hemophilia A. Adynovate can also be used for routine prophylaxis. The technical name of Adynovate is Antihemophilic factor (recombinant), PEGylated.

Adynovate is a clotting factor. Clotting factors work by supplying proteins missing in people with hemophilia.

How do I take it?
Prescribing information states that Adynovate is given as an intravenous injection.

Adynovate comes as a powder that must be reconstituted before injection.

Side effects
The FDA-approved label for Adynovate lists common side effects including headache and nausea.

Rare but serious side effects listed for Adynovate include pancreatitis and the development of inhibitors.

For more details about this treatment, visit:

Adynovate.com

Treatment of Hemophilia– Hemophilia Federation of America